Floatz logo

Tivantinib

Solid Neoplasm

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Namenda
NRG Oncology
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Emory University
Phase 1CCC
Larotrectinib
Children's Oncology Group
Phase 2CCC
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC
Veliparib
National Cancer Institute (NCI)
Phase 1CCC

View all 24 →

Same molecule, other indications

Tivantinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →